Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: Potential implication for prostate cancer therapy

Prostate

Volumn 71, Issue 13, 2011, Pages 1413-1419

  Makhov, Peter ^a   Kutikov, Alexander ^a   Golovine, Konstantin ^a   Uzzo, Robert G ^a   Canter, Daniel J ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

apoptosis; cancer; docetaxel; prostate; zinc

Indexed keywords

DOCETAXEL; ZINC;

APOPTOSIS; ARTICLE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOTOXICITY; DNA FRAGMENTATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; HUMANS; MALE; MYELOID PROGENITOR CELLS; PROSTATIC NEOPLASMS; TAXOIDS; ZINC;

EID: 80051668800     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21357     Document Type: Article

References (32)

1. Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M, Holtl W, Schramek P, Stackl W, Zielinski C, Reibenwein J,. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. J Urol 2007; 177 (6): 2141-2145, discussion 2145. (Pubitemid 46726414)
2. Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro MS, von Minckwitz G,. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13 (1): 49-59.
3. Jordan MA, Wilson L,. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4 (4): 253-265. (Pubitemid 38525281)
4. Bhalla KN,. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22 (56): 9075-9086. (Pubitemid 38121708)
5. Blagosklonny MV, Fojo T,. Molecular effects of paclitaxel: Myths and reality (a critical review). Int J Cancer 1999; 83 (2): 151-156. (Pubitemid 29449089)
6. Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV,. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 2005; 65 (10): 4401-4407. (Pubitemid 40775679)
7. Jordan MA, Toso RJ, Thrower D, Wilson L,. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90 (20): 9552-9556. (Pubitemid 23315823)
8. Blagosklonny MV, Robey R, Bates S, Fojo T,. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105 (4): 533-539. (Pubitemid 30127254)
9. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W,. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 2000; 6 (9): 3766-3773.
10. Costello LC, Franklin RB,. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998; 35 (4): 285-296. (Pubitemid 28235130)
11. Costello LC, Franklin RB,. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59 (4): 269-282.
12. Feustel A, Wennrich R, Schmidt B,. Serum-Zn-levels in prostatic cancer. Urol Res 1989; 17 (1): 41-42. (Pubitemid 19056887)
13. Franklin RB, Ma J, Zou J, Guan Z, Kukoyi BI, Feng P, Costello LC,. Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem 2003; 96 (2-3): 435-442. (Pubitemid 36900381)
14. Huang L, Kirschke CP, Zhang Y,. Decreased intracellular zinc in human tumorigenic prostate epithelial cells: A possible role in prostate cancer progression. Cancer Cell Int 2006; 6 (1): 10.
15. Franklin RB, Costello LC,. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 2007; 463 (2): 211-217. (Pubitemid 47030335)
16. Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, Magda D,. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005; 65 (24): 11676-11688. (Pubitemid 41821728)
17. Henry J,. 1996; Clinical diagnosis and management by laboratory methods. 19th edition. Philadelphia, PA: WB Saunders Co.
18. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P,. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999; 40 (3): 200-207. (Pubitemid 29334868)
19. Singh KK, Desouki MM, Franklin RB, Costello LC,. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006; 5: 14.
20. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE,. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006; 59 (1): 10-16. (Pubitemid 43076233)
21. Wei H, Desouki MM, Lin S, Xiao D, Franklin RB, Feng P,. Differential expression of metallothioneins (MTs) 1, 2 and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 2008; 7: 7.
22. Murata M, Gong P, Suzuki K, Koizumi S,. Differential metal response and regulation of human heavy metal-inducible genes. J Cell Physiol 1999; 180 (1): 105-113. (Pubitemid 29249718)
23. Uzzo RG, Leavis P, Hatch W, Gabai VL, Dulin N, Zvartau N, Kolenko VM,. Zinc inhibits nuclear factor-kappaB activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002; 8 (11): 3579-3583. (Pubitemid 35340736)
24. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH,. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20 (23): 2927-2936. (Pubitemid 33027760)
25. Huang M, Wei JN, Peng WX, Liang J, Zhao C, Qian Y, Dai G, Yuan J, Pan FY, Xue B, Sha JH, Li CJ,. The association of CaM and Hsp70 regulates S-phase arrest and apoptosis in a spatially and temporally dependent manner in human cells. Cell Stress Chaperones 2009; 14 (4): 343-353.
26. Cayrol C, Knibiehler M,. Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16 (3): 311-320. (Pubitemid 28052285)
27. Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG, Hannun YA,. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem 1997; 272 (30): 18530-18533. (Pubitemid 27318188)
28. Stennicke HR, Salvesen GS,. Biochemical characteristics of caspases-3, -6, -7, and -8. J Biol Chem 1997; 272 (41): 25719-25723. (Pubitemid 27438890)
29. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM,. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005; 24 (38): 5868-5877. (Pubitemid 43080078)
30. Bae SN, Lee YS, Kim MY, Kim JD, Park LO,. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR(R)) on human epithelial ovarian cancer cell line, OVCAR-3. Gynecol Oncol 2006; 103 (1): 127-136. (Pubitemid 44389866)
31. Untergasser G, Rumpold H, Plas E, Witkowski M, Pfister G, Berger P,. High levels of zinc ions induce loss of mitochondrial potential and degradation of antiapoptotic Bcl-2 protein in in vitro cultivated human prostate epithelial cells. Biochem Biophys Res Commun 2000; 279 (2): 607-614. (Pubitemid 32016762)
32. Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM,. Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res 2008; 14 (17): 5376-5384.